Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Apr 1;136(4):329-335.
doi: 10.1001/jamaophthalmol.2017.6836.

Detection of Glaucoma Progression in Individuals of African Descent Compared With Those of European Descent

Affiliations
Observational Study

Detection of Glaucoma Progression in Individuals of African Descent Compared With Those of European Descent

Carolina P B Gracitelli et al. JAMA Ophthalmol. .

Abstract

Importance: Individuals of African descent have been reported to be at higher risk for becoming visually impaired from glaucoma compared with individuals of European descent.

Objective: To investigate racial differences in longitudinal visual field variability and their impact on time to detect visual field progression.

Design, setting, and participants: This multicenter prospective observational cohort study included 236 eyes of 173 individuals of European descent and 235 eyes of 171 individuals of African descent followed up for a mean (SD) time of 7.5 (3.4) years.

Main outcomes and measures: Differences in test-retest variability and simulated time to detect progression in individuals of African descent and of European descent with glaucoma. Standard automated perimetry mean deviation values were regressed over time for each eye, and SD of the residuals was used as a measure of variability. Distributions of residuals were used in computer simulations to reconstruct "real-world" standard automated perimetry mean deviation trajectories under different assumptions about rate of change and frequency of testing. Times to detect progression were obtained for the simulated visual fields.

Results: Among the 344 patients, the mean (SD) age at baseline was 60.2 (10.0) and 60.6 (9.0) years for individuals of African descent and of European descent, respectively; 94 (52%) and 86 (48%) of individuals of African descent and of European descent were women, respectively. The mean SD of the residuals was larger in eyes of individuals of African descent vs those of European descent (1.45 [0.83] dB vs 1.12 [0.48] dB; mean difference: 0.33 dB; 95% CI of the difference, 0.21-0.46; P < .001). The eyes in individuals of African descent had a larger increase in variability with worsening disease (P < .001). When simulations were performed assuming common progression scenarios, there was a delay to detect progression in eyes of individuals of African descent compared with those of European descent. For a scenario with baseline mean deviation of -10 dB and rate of change of -0.5 dB/y, detection of progression in individuals of African descent was delayed by 3.1 (95% CI, 2.9-3.2) years, when considered 80% power and annual tests.

Conclusions and relevance: Patients of African descent with glaucoma showed increased visual field variability compared with those of European descent, resulting in delayed detection of progression that may contribute to explain higher rates of glaucoma-related visual impairment in individuals of African descent compared with those of European descent with glaucoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Zangwill reports receiving financial support from Carl Zeiss Meditec Inc, Heidelberg Engineering Inc, Merck & Co Inc, and Optovue Inc. Dr Girkin reports receiving financial support from the National Eye Institute, EyeSight Foundation of Alabama, Research to Prevent Blindness, Code, Carl Zeiss Meditec Inc, Heidelberg Engineering Inc, and SOLX Inc. Dr Weinreb reports receiving honoraria from Heidelberg Engineering Inc, Carl Zeiss Meditec, Genentech, Konan Medical, National Eye Institute, Neurovision, Optovue, Quark Pharmaceuticals, Reichert Technologies, Tomey Corporation, and Topcon Corporation and being a consultant for Alcon, Allergan Inc, AMATECK Inc, Bausch & Lomb, Carl Zeiss Meditec Inc, Forsight Biotherapeutics, and Topcon Corporation. Dr Liebmann reports being a consultant for Alcon, Allergan Inc, Bausch & Lomb, Carl Zeiss Meditech Inc, Diopysis, Heidelberg Engineering Inc, Merz Phamaceuticals, Quark Pharmaceuticals, Reichert Technologies, Sensimed, and Valeant Pharmaceuticals; financial support from Bausch & Lomb, Diopysis, Heidelberg Engineering Inc, National Eye Institute, New York Glaucoma Research Institute, Optovue Inc, Reichert Technologies, and Topcon Corporation; employment by Diopysis and Code; financial support from Heidelberg Engineering Inc and Code; being a consultant for SOLX Inc and Sustained Nanosystems; and has a patent with Sustained Nanosystems. Dr Medeiros reports receiving financial support from Alcon, Allergan Inc, Bausch & Lomb, Carl Zeiss Meditec Inc, Heidelberg Engineering Inc, Merck & Co Inc, National Eye Institute, Sensimed Inc, and Topcon Corporation and consulted for Alcon, Allergan Inc, Carl Zeiss Meditec Inc, Reichert Technologies, Allergan Inc, Carl Zeiss Meditec Inc, and Novartis. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Distribution of the SD of the Residuals in European and African Descent Groups
Figure 2.
Figure 2.. Association Between Visual Field Variability and Visual Field Severity
The nonlinear association between visual field variability and visual field severity modeled by splines in European and African descent groups. The main difference between the 2 groups was seen at mean deviation of approximately –12 dB.

Comment in

Similar articles

Cited by

References

    1. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901-1911. - PMC - PubMed
    1. Wilson R, Richardson TM, Hertzmark E, Grant WM. Race as a risk factor for progressive glaucomatous damage. Ann Ophthalmol. 1985;17(10):653-659. - PubMed
    1. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore Eye Survey. JAMA. 1991;266(3):369-374. - PubMed
    1. Kosoko-Lasaki O, Gong G, Haynatzki G, Wilson MR. Race, ethnicity and prevalence of primary open-angle glaucoma. J Natl Med Assoc. 2006;98(10):1626-1629. - PMC - PubMed
    1. Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study: prevalence of open angle glaucoma. Arch Ophthalmol. 1994;112(6):821-829. - PubMed

Publication types